NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Jinkushal Industries FY26 Revenue Jumps 48% to ₹313 Cr; PAT Declines to ₹12.4 Cr
Jinkushal Industries reported a robust 47.9% year-on-year growth in annual revenue, reaching ₹31,337.61 lakhs for FY26. Despite the top-line growth, net profit for the year declined by 22.7% to ₹1,243.60 lakhs, impacted by higher purchase costs and a significant rise in other expenses. A major concern for investors is the sharp spike in trade receivables, which surged from ₹8,869.95 lakhs to ₹21,750.65 lakhs, indicating potential working capital pressure. The company also announced the appointment of Promoter-MD Mr. Abhinav Jain as the CEO.
முக்கிய அம்சங்கள்
Annual revenue from operations increased 47.9% YoY to ₹31,337.61 lakhs in FY26.Net profit for the full year FY26 fell to ₹1,243.60 lakhs compared to ₹1,607.97 lakhs in FY25.Trade receivables witnessed a massive 145% increase, reaching ₹21,750.65 lakhs as of March 31, 2026.Total borrowings nearly doubled to ₹10,024.59 lakhs to fund operations and inventory.Mr. Abhinav Jain appointed as Chief Executive Officer (CEO) effective June 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution and monitor the company's cash flow cycle, as the massive increase in receivables suggests aggressive credit terms or collection delays. The decline in profitability despite higher scale needs further investigation into margin sustainability.
Jinkushal Industries Appoints Promoter Abhinav Jain as CEO Effective June 1, 2026
Jinkushal Industries Limited has announced the appointment of Mr. Abhinav Jain as the company's Chief Executive Officer, effective June 1, 2026. Mr. Jain is a Promoter and the current Managing Director, having been associated with the firm since September 25, 2017. With over 7 years of experience in construction equipment exports and international business development, he has been a key driver of the company's global market expansion. His leadership was notably recognized with the 'Business Leader of the Year – 2023' award by CEO Insights.
முக்கிய அம்சங்கள்
Mr. Abhinav Jain appointed as CEO starting June 1, 2026, while continuing his role as Promoter and MDPossesses over 7 years of specialized experience in construction equipment exports and supply chain managementAssociated with the company for nearly 9 years, contributing to strategic planning and international growthHolds a B.Tech in Mechanical Engineering from VIT University and was awarded Business Leader of the Year in 2023
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step for leadership continuity and stability, as the new CEO is a promoter with a proven track record in the company's core export business. Monitor for further strategic shifts in international market expansion under his formal CEO tenure.
India Pesticides FY26 Revenue Crosses ₹1,000 Cr Milestone; PAT Surges 45.8% YoY
India Pesticides Limited (IPL) achieved a significant milestone in FY26, with annual revenue crossing the ₹1,000 crore mark to reach ₹1,078 crores, a 27.9% YoY growth. Profitability improved sharply as PAT rose 45.8% to ₹120 crores and EBITDA margins expanded to 18%. The company reported strong Q4 performance driven by a 30% volume growth and a 50% surge in domestic sales. Management is focusing on backward integration and the expansion of the Hamirpur facility to sustain this momentum.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue grew 27.9% YoY to ₹1,078 crores, exceeding the company's target.Full-year PAT increased by 45.8% to ₹120 crores, while EBITDA rose 44.7% to ₹194 crores.Q4 domestic sales surged to ₹183 crores from ₹118 crores, representing over 50% growth driven by herbicides.Formulation capacity has been successfully scaled up to 10,000 metric tonnes.Commissioned a new intermediate plant for backward integration using in-house R&D to reduce import dependency.
👀 கவனிக்க வேண்டியவை
Investors should note the successful scale-up and margin improvement despite global geopolitical tensions. The focus should remain on the timely execution of the Hamirpur facility expansion, which is the key catalyst for future capacity growth.
WIPL Announces Financial Results for the Fiscal Year Ended March 31, 2026
The Western India Plywoods Limited (WIPL) has officially submitted its financial results for the fiscal year ending March 31, 2026, following a board meeting held on May 25, 2026. This announcement marks the completion of the annual reporting cycle and regulatory compliance for the fiscal year. While specific profit and loss figures were not detailed in the summary brief, the filing allows investors to now access the full audited statements. This is a routine but critical disclosure for assessing the company's annual performance.
முக்கிய அம்சங்கள்
Board meeting concluded on May 25, 2026, to approve annual financial results.Submission covers the full fiscal year period ending March 31, 2026.The company has complied with exchange listing requirements for financial disclosure.Full audited financial statements are now available for shareholder review.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed profit and loss statements to identify trends in revenue growth and operating margins. Compare the FY2026 performance against previous years to evaluate the company's trajectory in the wood products industry.
India Pesticides Crosses ₹1,000 Cr Revenue Milestone; FY26 PAT Jumps 45.8% to ₹120 Cr
India Pesticides Limited (IPL) reported a strong financial performance for FY26, crossing the ₹1,000 crore revenue milestone with a total income of ₹1,078 crore, up 27.9% YoY. The company's profitability saw significant growth, with EBITDA rising 44.7% to ₹194 crore and Net Profit increasing 45.8% to ₹120 crore. This growth was driven by a 29% increase in volumes across domestic and international markets, particularly in the herbicide and intermediate segments. The EBITDA margin improved to 18.0%, reflecting better capacity utilization and operational efficiencies.
முக்கிய அம்சங்கள்
Total Income for FY26 reached ₹1,078 Cr, marking a 27.9% YoY growth and crossing the ₹1,000 Cr milestone.Net Profit (PAT) surged by 45.8% YoY to ₹120 Cr, with PAT margins standing at 11.1%.EBITDA grew by 44.7% YoY to ₹194 Cr, with margins expanding to 18.0% due to improved operational efficiencies.Volume growth of approximately 29% was recorded across both Indian and international markets, driven by demand for herbicides.Technical & API segments remained the core revenue drivers, contributing 71% to the total revenue in Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should view the strong volume growth and margin expansion as a sign of robust operational health and successful capacity utilization. The crossing of the ₹1,000 Cr revenue mark and focus on backward integration suggest a positive long-term trajectory for the company.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
India Pesticides Recommends ₹0.75 Dividend; Sets AGM for August 31, 2026
India Pesticides Limited (IPL) has recommended a dividend of ₹0.75 per equity share of face value ₹1 for the financial year ended March 31, 2026. The company has fixed August 24, 2026, as the record date to determine shareholder eligibility for the payout. The 41st Annual General Meeting (AGM) is scheduled to be held on August 31, 2026, via video conferencing. Furthermore, the board approved the audited financial results for FY26, which received an unmodified audit opinion from the statutory auditors.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.75 per equity share (75% of face value) for FY 2025-26.Fixed August 24, 2026, as the record date for dividend eligibility.The 41st Annual General Meeting is scheduled for August 31, 2026.Statutory auditors issued an unmodified (clean) audit opinion on standalone and consolidated results.Re-appointed M/s Seth & Associates as Internal Auditors and M/s Honey Singh & Associates as Cost Auditors for FY 2026-27.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold shares before the record date of August 24, 2026. The clean audit report is a positive sign regarding the company's financial transparency and reporting integrity.
India Pesticides Q4 & FY26 Results: Board Recommends ₹0.75 Dividend per Share
India Pesticides Limited (IPL) has approved its audited financial results for the quarter and financial year ended March 31, 2026. The Board has recommended a final dividend of ₹0.75 per equity share, representing 75% of the face value. The company's statutory auditors have issued an unmodified audit opinion, indicating a clean bill of health for the financial statements. Additionally, the company has re-appointed its internal and cost auditors for the 2026-27 fiscal year.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.75 per equity share of face value ₹1 for FY 2025-26.Set Monday, August 24, 2026, as the Record Date for dividend eligibility.Statutory auditors issued an unmodified audit opinion on both standalone and consolidated results.Re-appointed M/s Seth & Associates as Internal Auditors and M/s Honey Singh & Associates as Cost Auditors for FY 2026-27.The 41st Annual General Meeting (AGM) is scheduled for August 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial statements for margin trends and top-line growth. Existing shareholders must hold the stock until the August 24 record date to be eligible for the ₹0.75 dividend.
Jinkushal Industries Announces Leadership Transition; Abhinav Jain Appointed Managing Director
Jinkushal Industries Limited has announced a strategic leadership reshuffle effective May 16, 2026. Mr. Anil Kumar Jain, who has over 37 years of industry experience, will transition from Managing Director to Chairman cum Executive Director to provide strategic oversight. Mr. Abhinav Jain, previously a Whole-Time Director with 7 years of experience in export and market development, has been appointed as the Managing Director for a five-year term. This transition appears to be a planned succession within the promoter family to drive the company's next phase of global expansion.
முக்கிய அம்சங்கள்
Mr. Abhinav Jain appointed as Managing Director for a 5-year term effective May 16, 2026Mr. Anil Kumar Jain re-designated as Chairman cum Executive Director to focus on governance and strategic guidanceAbhinav Jain brings 7+ years of experience and was awarded 'Business Leader of the Year (2023)' by CEO InsightsAnil Kumar Jain retains a leadership role with over 37 years of experience in automotive, logistics, and mining sectorsThe appointments are subject to shareholder approval at the upcoming General Meeting
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's operational performance under the new Managing Director to see if the focus on global expansion translates into revenue growth. No immediate portfolio changes are recommended as this is a structured leadership transition within the promoter group.
Cipla Q4 FY26 Revenue Reaches ₹6,541 Cr; One India Business Grows 15% YoY
Cipla reported a robust Q4 FY26 with revenue of ₹6,541 crores and full-year revenue of ₹28,163 crores. The One India business led growth at 15% YoY, while the North America segment achieved $780 million in annual revenue. EBITDA margins for the year remained healthy at 21%, supported by a 66% gross margin. The company is pivoting towards complex generics and biosimilars, with 40-50 new filings targeted over the next three years.
முக்கிய அம்சங்கள்
One India business grew 15% YoY in Q4; Foracort brand surpassed ₹1,000 crore in annual revenue.North America annual revenue reached $780 million with the first generic Ventolin approval from a U.S. facility.Full-year EBITDA margin stood at 21% with a PAT of ₹3,879 crores and ROIC of 22.9%.R&D spend for FY26 was ₹1,974 crores (7% of revenue) focusing on peptides and biosimilars.EMEU operations scaled to become a $400 million-plus business unit despite geopolitical challenges.
👀 கவனிக்க வேண்டியவை
Maintain a positive outlook given the strong domestic chronic portfolio and the strategic shift toward complex generics in the U.S. Watch for the commercial launch of the 4 respiratory assets planned for FY27.
Cipla Appoints Sushrut Kulkarni as Global IPD Chief; Grants 7.7 Lakh ESOPs and ESARs
Cipla has announced the appointment of Sushrut Kulkarni as President & Global Chief of Integrated Product Development (IPD), effective May 18, 2026. Mr. Kulkarni brings over 30 years of experience, having previously served as Global Head of IPDO at Dr. Reddy's Laboratories. The Board also approved the grant of 1,76,389 stock options and 5,96,244 Employee Stock Appreciation Rights (ESARs) at a nominal exercise price of INR 2. Additionally, the company's 90th Annual General Meeting is scheduled for June 25, 2026.
முக்கிய அம்சங்கள்
Appointment of Sushrut Kulkarni (ex-Dr. Reddy's) as Global Chief of Integrated Product DevelopmentGrant of 1,76,389 stock options under ESOS 2013-A and 5,96,244 ESARs under ESAR 2021Exercise price for both options and ESARs set at a nominal INR 2 per share90th Annual General Meeting (AGM) to be convened on June 25, 2026Appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27
👀 கவனிக்க வேண்டியவை
Investors should view the hiring of a seasoned R&D leader from a major competitor as a positive step for Cipla's product pipeline. Monitor the upcoming AGM for further strategic updates and long-term growth guidance.
Cipla FY26 Revenue Hits Record INR 28,163 Cr; EBITDA Margins Contract to 21%
Cipla achieved its highest-ever annual revenue of INR 28,163 Cr in FY26, supported by double-digit growth in the India and North America segments. Despite the revenue growth, EBITDA margins contracted to 21.0% from 25.9% in FY25, and PAT declined to INR 3,879 Cr from INR 5,273 Cr. The company maintains a very strong balance sheet with a net cash position exceeding $1 billion (INR 11,140 Cr). Key strategic milestones include the approval of the first AB-rated gVentolin in the US and crossing the $400 Mn benchmark in North American quarterly revenue.
முக்கிய அம்சங்கள்
Annual revenue reached a record INR 28,163 Cr, with the One India business contributing 45% of total sales.FY26 EBITDA stood at INR 5,925 Cr with a margin of 21.0%, a decrease from the 25.9% margin reported in FY25.North America revenue grew 14% YoY in Q4 to $155 Mn, aided by the approval of gVentolin with CGT status.R&D investment for FY26 was INR 1,974 Cr, accounting for 7.0% of total revenue to support a complex generic pipeline.Net cash position strengthened to INR 11,140 Cr, providing significant capital for potential M&A and expansion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin recovery trajectory and the commercial launch of gVentolin in the US. While revenue growth is robust, the year-on-year decline in profitability suggests cost pressures that need to be managed.
Cipla Q4 FY26 PAT Declines to ₹555 Cr; Board Recommends ₹13 Dividend
Cipla reported a weak Q4 FY26 with consolidated PAT falling significantly to ₹555 Cr from ₹1,222 Cr in the previous year. While the One-India business grew by a robust 15% YoY, the North America segment faced a 26% revenue decline during the quarter. Despite quarterly headwinds, the company achieved its highest-ever annual revenue of ₹28,163 Cr for the full year FY26. The company maintains a strong net cash position of ₹10,526 Cr and has proposed a final dividend of ₹13 per share.
முக்கிய அம்சங்கள்
Q4 FY26 PAT stood at ₹555 Cr, down from ₹1,222 Cr in Q4 FY25, with EBITDA margins contracting to 15.2%.One-India business grew 15% YoY in Q4, driven by double-digit growth across prescription, generics, and consumer health.North America revenue declined 26% YoY to ₹1,414 Cr in Q4, though it secured approval for the first AB-rated gVentolin.Full-year FY26 revenue reached a record ₹28,163 Cr with an annual EBITDA margin of 21.0%.Board recommended a final dividend of ₹13 per equity share (650% of face value).
👀 கவனிக்க வேண்டியவை
Investors should monitor the reasons behind the sharp margin contraction and North American revenue decline in Q4. While the India business remains a strong growth engine, the quarterly earnings miss may lead to short-term price volatility.
Cipla Receives USFDA Approval for First Generic Ventolin® HFA; Market Size ~$1.5 Billion
Cipla has received final USFDA approval for the first AB-rated generic version of Ventolin® HFA, targeting a U.S. albuterol market valued at approximately $1.5 billion. The product, Albuterol Sulfate Inhalation Aerosol, is scheduled for launch in the first half of FY 2026-27. This approval reinforces Cipla's leadership in the complex respiratory segment, where it already holds a significant market share. Manufacturing will be conducted at the company's dedicated inhalation facility in Fall River, Massachusetts, enhancing its domestic U.S. manufacturing footprint.
முக்கிய அம்சங்கள்
First AB-rated generic therapeutic equivalent of Ventolin® HFA approved by USFDATargets a total U.S. albuterol market opportunity of approximately $1.5 billionCommercial launch planned for H1 FY 2026-27 from the Fall River, Massachusetts facilityStrengthens Cipla's position as the 3rd largest player in the US Gx (Repulses + MDI) categoryVertically integrated inhalation platform used to ensure supply resilience and quality
👀 கவனிக்க வேண்டியவை
This approval is a significant milestone in Cipla's complex generics strategy and should be viewed as a long-term revenue driver for its U.S. business. Investors should monitor the ramp-up in market share and potential margin expansion following the H1 FY27 launch.
Cipla Receives 2 USFDA Observations for Goa Manufacturing Facility
The USFDA conducted a routine cGMP and Pre-Approval Inspection at Cipla's Verna, Goa facility from April 6 to April 17, 2026. The inspection concluded with the issuance of two observations in Form 483. Cipla has committed to addressing these observations comprehensively within the stipulated timeframe. While observations are a standard part of the regulatory process, the nature of these findings will determine future product approvals from this site.
முக்கிய அம்சங்கள்
USFDA inspection conducted at Verna, Goa facility from April 6 to April 17, 2026Company received 2 inspectional observations in Form 483Inspection covered routine cGMP and Pre-Approval Inspection (PAI) protocolsCipla committed to addressing observations within the stipulated time
👀 கவனிக்க வேண்டியவை
Monitor the company's response and the USFDA's final classification of the facility. Since there are only two observations, the risk of a Warning Letter is typically lower, but clarity on the severity is needed.
Cipla MD & CEO Umang Vohra to Step Down; Achin Gupta to Take Charge from April 2026
Cipla has announced a major leadership transition as Mr. Umang Vohra will conclude his 10-year tenure as Managing Director and Global CEO on March 31, 2026. Mr. Achin Gupta is set to take over the leadership role, supported by a newly designated senior management team including Saurabh Gambhir (Strategy & M&A) and Satyavan Manikani (Global Portfolio). The transition appears well-planned with a long lead time, ensuring stability in the company's strategic direction. This change marks the end of a significant era of growth and digital transformation under Vohra's leadership.
முக்கிய அம்சங்கள்
Mr. Umang Vohra to resign as MD & CEO effective April 1, 2026, after completing a 10-year tenure.Mr. Achin Gupta to be appointed as the new Managing Director and Global Chief Executive Officer.Two key executives, Saurabh Gambhir and Satyavan Manikani, elevated to Senior Management Personnel (SMP) status.The leadership change follows the completion of Vohra's current term and his decision not to seek re-appointment.Transition includes a focus on Strategy, M&A, and Global Portfolio management under the new CEO's direct reports.
👀 கவனிக்க வேண்டியவை
Investors should maintain a neutral stance as the transition is planned well in advance, minimizing immediate disruption. Monitor for any shifts in long-term strategy or capital allocation priorities once Achin Gupta officially takes charge in 2026.
Cipla Shareholders Approve Achin Gupta as MD & Global CEO with Over 99% Support
Cipla Limited has announced the successful passage of four key resolutions via postal ballot, including the appointment of Mr. Achin Gupta as Managing Director and Global CEO. The resolution for his appointment and remuneration received overwhelming support, with 99.86% and 99.63% votes in favor, respectively. While the re-appointment of Independent Director Mr. P.R. Ramesh was also approved with 83.01% total favor, it faced notable institutional resistance with 28.3% of institutional votes cast against it. Overall, the voting results confirm a stable transition in the company's top leadership.
முக்கிய அம்சங்கள்
Mr. Achin Gupta officially appointed as Managing Director and Global CEO with 99.86% shareholder approval.Remuneration package for the new MD & CEO cleared with 99.63% of votes in favor.Re-appointment of Independent Director P.R. Ramesh passed with 83.01% support, despite 110.58 million institutional votes against.Total voter participation was high at 80.58%, representing 650.9 million out of 807.78 million total shares.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the clear mandate given to the new CEO, which ensures management stability. Monitor for any strategic shifts in global operations under Mr. Achin Gupta's leadership.
Cipla Global Chief Scientific Officer Pradeep Bhadauria Resigns Effective March 31, 2026
Cipla Limited has announced the resignation of Mr. Pradeep Bhadauria from his role as Global Chief Scientific Officer and member of the Management Council. Mr. Bhadauria was an employee of Cipla USA Inc., a wholly owned subsidiary, and is leaving to pursue interests outside the organization. His tenure will officially conclude on March 31, 2026. This leadership change is noteworthy as the CSO role is critical for the company's R&D and product pipeline strategy.
முக்கிய அம்சங்கள்
Mr. Pradeep Bhadauria resigns as Global Chief Scientific Officer and Management Council member.The resignation is effective from the close of business on March 31, 2026.Mr. Bhadauria was an employee of Cipla USA Inc., a 100% subsidiary of the company.The departure is attributed to the executive pursuing interests outside of Cipla.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of a successor to ensure continuity in Cipla's complex generics and R&D pipeline. No immediate action is required as the transition period allows for a planned handover.
Cipla to Invest $100M in US Subsidiary and Merge Inzpera Healthsciences
Cipla's board has approved a significant investment of up to USD 100 million in its subsidiary Cipla (EU) Limited to fund the capital expenditure and working capital needs of InvaGen Pharmaceuticals in the US. Additionally, the company is merging its wholly-owned subsidiary Inzpera Healthsciences to streamline operations and leverage marketing strengths in the pediatric segment. Management changes were also announced, including the designation of P R Ramesh as Vice-Chairman effective April 1, 2026. These moves reflect a strategic focus on strengthening international operations and domestic efficiency.
முக்கிய அம்சங்கள்
Approved investment of up to USD 100 million in Cipla (EU) Limited for onward financial assistance to InvaGen Pharmaceuticals Inc.Scheme of Amalgamation approved for Inzpera Healthsciences Limited, which had a turnover of ₹26.74 crore in FY25.Mr. P R Ramesh designated as Vice-Chairman of the Company with effect from April 1, 2026.The merger of Inzpera will involve no cash consideration or share swap as it is a wholly-owned subsidiary.Investment in InvaGen is specifically targeted at capital expenditure, working capital, and general corporate purposes.
👀 கவனிக்க வேண்டியவை
Investors should view the $100M capital infusion as a positive sign of commitment to the US market growth. The merger of Inzpera is a routine but efficient consolidation that simplifies the corporate structure without any equity dilution.
Cipla USA Initiates Recall of Lanreotide Injection Leading to Temporary Supply Shortage
Cipla Limited's wholly owned subsidiary, Cipla USA Inc., has announced a recall of all unexpired batches of Lanreotide Injection. This decision was made following discussions with Pharmathen International S.A. and will result in a temporary lack of supply for this product in the market. The recall follows previous disclosures made by the company in January and February 2026, indicating an ongoing regulatory or quality issue. This development is expected to impact the company's US revenue from this specific product line in the near term.
முக்கிய அம்சங்கள்
Cipla USA Inc. to recall all unexpired batches of Lanreotide Injection from the market.The recall will lead to a temporary lack of supply for the injection in the US market.Decision follows discussions with partner Pharmathen International S.A. and previous updates in early 2026.The move is a disclosure under Regulation 30 of SEBI Listing Regulations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the duration of the supply disruption and assess the potential impact on Cipla's US generic revenue. Watch for further management commentary on the specific reasons behind the recall and the timeline for market re-entry.
India Pesticides Shareholders Approve Director Re-appointments with Over 99.99% Majority
India Pesticides Limited (IPL) has successfully passed three special resolutions via postal ballot with near-unanimous shareholder support. The resolutions included the re-appointment of Dr. Madhu Dikshit as Chairperson and Mr. Mohan Vasant Tanksale as Independent Director for second five-year terms. Additionally, shareholders approved the regularization of Mr. Arun Kumar Jain as an Independent Director. The voting turnout was significant, with approximately 65.39% of total shares participating in the electronic voting process.
முக்கிய அம்சங்கள்
Dr. Madhu Dikshit re-appointed as Chairperson with 7,53,01,092 votes in favor (99.995%)Mr. Mohan Vasant Tanksale's second 5-year term approved with 99.995% of valid votes castMr. Arun Kumar Jain regularized as Independent Director with 99.996% shareholder approvalTotal voting participation reached 65.39% of the 11,51,63,508 total equity shares
👀 கவனிக்க வேண்டியவை
The overwhelming support for these board appointments indicates strong shareholder confidence in the company's leadership and governance. Investors can expect continuity in strategic oversight as these experienced directors continue their tenures.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
